04:28 PM EST, 03/08/2024 (MT Newswires) -- Janux Therapeutics ( JANX ) posted a Q4 net loss late Friday of $0.25 per diluted share, narrower than a loss of $0.39 a year ago.

Analysts polled by Capital IQ expected a loss of $0.41.

Collaboration revenue for the quarter ended Dec. 31 was $2.46 million, down from $2.85 million a year earlier.

Analysts surveyed by Capital IQ expected revenue of $0.74 million.

The company said that as of Dec. 31, it had cash, cash equivalents and short-term investments of $344 million, up from $327 million a year earlier.

"With our substantial cash runway we feel well-positioned to execute on our clinical plan," said CEO David Campbell.